SoftBank leads $150M round into Dewpoint as condensate biotech nears clinic
In another market, Dewpoint Therapeutics may have gone public about now and raised a princely sum.
Although they’re still around two years from human trials, the biotech already has blue-chip VC backers, three Big Pharma partnerships, and a compelling story about being the first and biggest entrant to a new field of biology. But Wall Street isn’t buying much of anything these days.
So Dewpoint will have to settle for the next best thing: a venture capital firm that often acts as if it has as much money as Wall Street — SoftBank.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.